Drupal.behaviors.print = function(context) {window.print();window.close();}>
With $2.85M in Funding, ETH Zurich Spinout ProteoMedix Begins Validating Prostate Cancer Panel
February 10, 2012
With $2.85M in Funding, ETH Zurich Spinout ProteoMedix Begins Validating Prostate Cancer Panel
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
ETH Zurich Scientists Propose Protein Biomarker Discovery Strategy Guided by Cancer Genetics
February 11, 2011 / ProteoMonitor
Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter
GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor
Wall Street Closely Tracking Validation Data on Genomic Health's Oncotype DX Prostate Cancer Test
April 3, 2013 / Pharmacogenomics Reporter
JP Morgan Healthcare Conference, Day One: Myriad Genetics; Bruker; Genomic Health; Qiagen; Waters
January 8, 2013 / GenomeWeb Daily News